DALLAS, September 8, 2011 /PRNewswire/ --
The report " Global Clinical Trials Market (2007 - 2010)" analyses the total number of clinical trials conducted globally from 2007 to 2010 by phases, study design, indications, and major market drivers, restraints, and opportunities for the clinical trials market in North America, South America, Europe, and Asia.
Browse market data tables and in-depth TOC on Global Clinical Trials Market (2007 - 2010)
Early buyers will receive 10% customization of reports.
Clinical trials market now witness a paradigm shift. Naïve heterogeneous patient populations in the developing nations are opening up new avenues for the clinical trials market. Developing countries also offer faster go to market which is triggering major pharmaceutical companies to direct their investment in these regions. Apart from this, stringent regulations and tight R&D budgets in the Pharma-Biotech industry are also forcing companies to move to east. This scenario has further boosted the alliances between the pharma-biotech companies and the clinical research organizations, with the latter accounting for major chunk of the trials conducted.
Today, emerging countries account for the largest share of the phase II/III (prime stages) clinical trials conducted globally with major focus on oncology, Alzheimer's, metabolic and cardiovascular diseases. Support from the respective government bodies is one of the major factors affecting the clinical trials market. Clinical trials sponsored by the industry have a much higher share i